Case Report: Temporary Molecular Relapse of Myeloid Leukemias in the Setting of COVID-19 and Viral-Induced Immunosuppression
LabMed · 2025
DOI: 10.3390/labmed2010002 ↗Kurz gefasst
Fallbericht in der Zeitschrift LabMed, 2025. Verfasst von Ishan Bhatia und 2 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute promyelocytic leukemia (APML) is one of the most curable leukemia subtypes, where the majority of patients achieve complete remission and also deep molecular remission after therapy, characterized by a PCR-undetectable state. Similarly, chronic myelogenous leukemia (CML) is a leukemia where, thanks to effective targeted treatment with tyrosine kinase inhibitors (TKIs), deep remission detectable only by PCR has become part of the routine management of these patients. Here, we describe a patient who was PCR-negative after induction and consolidation with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) and stayed PCR-undetectable for 13 months post-consolidation, later experiencing molecular relapse following mild SARS-CoV-2 infection. The patient was able to reestablish molecular remission again without anti-leukemic therapy several weeks later. She remained PCR-negative for the next 42 months. Viral infection-triggered immunosuppression, as in our case, offers a possible explanation for the temporary loss of molecular remission seen in leukemia patients monitored by PCR. Our first case illustrates this period of convalescence from viral infection, which was maybe accompanied by loss of molecular response. Viral infections and temporary immunosuppression may be a culprit in cases where molecular responses are lost temporarily. This loss of the PCR-undetectable state may have implications for other cancer patients where PCR monitoring is used. Thus, our observation may have broader implications for other patients, especially those with CML. We further enforce these findings by describing a second patient with CML who experienced temporary molecular relapse in the setting of post-viral syndrome.
Zitieren
APA
Bhatia, I., Hutchinson, L., & Cerny, J. (2025). Case Report: Temporary Molecular Relapse of Myeloid Leukemias in the Setting of COVID-19 and Viral-Induced Immunosuppression. LabMed. https://doi.org/10.3390/labmed2010002
Vancouver
Bhatia I, Hutchinson L, Cerny J. Case Report: Temporary Molecular Relapse of Myeloid Leukemias in the Setting of COVID-19 and Viral-Induced Immunosuppression. LabMed. 2025. doi:10.3390/labmed2010002
BibTeX
@article{Bhatia2025,
author = {Bhatia, Ishan and Hutchinson, Lloyd and Cerny, Jan},
title = {Case Report: Temporary Molecular Relapse of Myeloid Leukemias in the Setting of COVID-19 and Viral-Induced Immunosuppression},
journal = {LabMed},
year = {2025},
doi = {10.3390/labmed2010002}
}
EUVIMED